TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Niagen Bioscience ( (NAGE) ) has issued an announcement.
On November 4, 2025, Niagen Bioscience reported a 33% increase in net sales for the third quarter of 2025, reaching $34.0 million, driven by strong Tru Niagen® sales and improved e-commerce performance. The company also launched AboutNAD®, a digital platform for NAD+ research, and expanded its distribution network for Niagen Plus™ IV therapies, reinforcing its leadership in the NAD+ market. The company reaffirmed its full-year outlook for 25% to 30% net sales growth, highlighting its strategic initiatives and operational improvements.
The most recent analyst rating on (NAGE) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
Spark’s Take on NAGE Stock
According to Spark, TipRanks’ AI Analyst, NAGE is a Neutral.
Niagen Bioscience’s strong financial performance is a key strength, driven by improved profitability and cash flow. However, technical indicators suggest bearish momentum, and the stock’s valuation is moderate with no dividend yield. The absence of earnings call data and corporate events limits further insights.
To see Spark’s full report on NAGE stock, click here.
More about Niagen Bioscience
Niagen Bioscience, Inc. operates in the health and wellness industry, focusing on products that enhance cellular health through NAD+ boosting. The company’s primary products include Tru Niagen® and Niagen® ingredients, with a market focus on both consumer products and clinical-grade therapies.
Average Trading Volume: 1,105,806
Technical Sentiment Signal: Hold
Current Market Cap: $576.6M
Find detailed analytics on NAGE stock on TipRanks’ Stock Analysis page.